论文部分内容阅读
目的:在蛋白水平上研究国人弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)分子分型的蛋白表型特点,为DLBCL的病理诊断、预后和治疗提供依据。方法:取DLBCL标本52例行HE染色和免疫组化染色。在形态学分型的基础上,利用CD10、MUM1和bcl-6免疫标记对DLBCL进行分子分型,分为生发中心样B细胞样组(germi-nal center B-cell—like,GCB)和非生发中心样B细胞样组(non-germinal center B-cell-like,non-GCB),分析其在DLBCL中的构成比,及CD10、MUM1和bcl-6的表达情况。结果:本组DLBCL中,non-GCB的构成比超过GCB(69.2%/30.8%);统计学分析表明,GCB组间CD10、bd-6、CD10/bcl-6的表达率的差异有显著性意义,其中CD10的表达率最高,bcl-6其次,CD10/bcl-6最低;non-GCB组间MUM1、MUM1/bcl-6的表达率的差异有显著性意义。结论:我国的DLBCL多起源于后生发中心B细胞,以non-GCB为主,预后较差。DLBCL在CD10、MUM1和bcl-6表达的差异对判定GCB组和non-GCB组有意义。
OBJECTIVE: To study the phenotypic characteristics of molecular differential typing of diffuse large B-cell lymphoma (DLBCL) at the protein level in order to provide evidence for the pathological diagnosis, prognosis and treatment of DLBCL. Methods: Fifty-two DLBCL specimens were stained with HE and immunohistochemistry. On the basis of morphological typing, molecular typing of DLBCL was performed using CD10, MUM1 and bcl-6 immunolabeling and classified into germinal-centric B-cell-like (GCB) Non-germinal center B-cell-like (non-GCB) was used to analyze its constitutional ratio in DLBCL and the expression of CD10, MUM1 and bcl-6. Results: The ratio of non-GCB to DLBCL in this group was higher than that of GCB (69.2% / 30.8%). Statistical analysis showed that there were significant differences in the expression rates of CD10, bd-6 and CD10 / bcl- Among them, the expression rate of CD10 was the highest, followed by bcl-6 and the lowest was CD10 / bcl-6. There was significant difference in the expression rates of MUM1 and MUM1 / bcl-6 between non-GCB groups. Conclusion: DLBCL in China mostly originated from B-cell of germinal center, mainly non-GCB, with poor prognosis. The differences in the expression of DLBCL at CD10, MUM1 and bcl-6 were significant for the determination of GCB and non-GCB groups.